Decoy Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Rhea-AI Impact

(Neutral)

Rhea-AI Sentiment

(Neutral)

Rhea-AI Summary

Decoy Therapeutics (Nasdaq: DCOY) announced it regained compliance with Nasdaq Listing Rule 5550(a)(2) (the Minimum Bid Price Requirement) effective March 31, 2026. The company is reported to be in compliance with all other continued listing requirements, but will be subject to a Mandatory Panel Monitor for one year from that date.

If the Listing Qualifications Staff finds renewed noncompliance during the one-year monitoring period, Nasdaq may issue a delisting determination letter and the company could request a hearing with the Nasdaq Hearings Panel.

Positive

Regained Nasdaq minimum bid price compliance on March 31, 2026
Now in compliance with all other applicable Nasdaq continued listing requirements

Negative

Subject to a Mandatory Panel Monitor for one year from March 31, 2026
Possible delisting if Listing Qualifications Staff finds noncompliance during the monitoring period

Key Figures

Monitoring period: 1 year

1 metrics

Monitoring period 1 year Nasdaq Mandatory Panel Monitor starting from Mar 31, 2026

Market Reality Check

Price: $6.32 Vol: Volume 16,537 is 0.48x th...

low vol

$6.32 Last Close

Volume Volume 16,537 is 0.48x the 20-day average, indicating subdued trading ahead of this compliance update. low

Technical Shares at $6.32 are trading below the $8.61 200-day MA and sit 62.65% under the 52-week high, just 6.4% above the 52-week low.

Historical Context

5 past events · Latest: Mar 11 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 11	AI partnership launch	Positive	-4.8%	Announced AI-driven peptide design and simulation platform with Quantori and Google Cloud.
Mar 05	Reverse stock split	Neutral	-11.3%	Approved 1-for-12 reverse split aimed at regaining Nasdaq minimum bid compliance.
Feb 11	Investor platform join	Positive	-3.0%	Joined Webull Corporate Connect to broaden communication with investors and shareholders.
Feb 05	Investor webinar	Positive	-1.6%	Planned presentation in Webull webinar highlighting antiviral peptide conjugate therapeutics.
Feb 04	Access agreement update	Positive	-7.6%	Discussed Global Access Commitment Agreement with Gates Foundation and IMP3ACT platform plans.

Pattern Detected

Recent positive operational and strategic news has repeatedly been followed by negative 24-hour price reactions.

Recent Company History

Over the past few months, Decoy announced a 1-for-12 reverse stock split on Mar 5, 2026, an AI-driven peptide design partnership with Quantori on Mar 11, 2026, and several investor-engagement initiatives, including Webull Corporate Connect participation and a Gates Foundation-related access segment in early February. Each event was followed by a negative 24-hour price reaction, suggesting a pattern where constructive corporate developments have not translated into short-term price strength ahead of today’s compliance news.

Market Pulse Summary

This announcement confirms Decoy regained compliance with Nasdaq’s Minimum Bid Price Requirement and...

Analysis

This announcement confirms Decoy regained compliance with Nasdaq’s Minimum Bid Price Requirement and entered a one-year Mandatory Panel Monitor period from Mar 31, 2026. That follows earlier steps such as the 1-for-12 reverse split and strategic initiatives around AI and investor outreach. Investors evaluating this update may focus on the company’s ability to sustain its bid price through the monitoring window and how future milestones support listing stability.

Key Terms

listing rule 5550(a)(2), minimum bid price requirement, mandatory panel monitor, nasdaq hearings panel

4 terms

listing rule 5550(a)(2) regulatory

"regained compliance with Listing Rule 5550(a)(2), the Minimum Bid Price Requirement"

Listing Rule 5550(a)(2) is a Nasdaq listing standard that sets a minimum share-price requirement for securities to be listed or to remain listed on the Nasdaq Capital Market. It matters to investors because falling below that minimum can trigger delisting reviews or increased volatility, much like a safety bar on a ride — if a stock can’t meet the height requirement, it risks being removed from the exchange, which can reduce liquidity and access for buyers and sellers.

minimum bid price requirement regulatory

"Listing Rule 5550(a)(2), the Minimum Bid Price Requirement and is now in compliance"

A minimum bid price requirement is a rule that a stock must trade above a set price for a specified period to stay listed on an exchange. It matters to investors because falling below that threshold can trigger warnings or removal from the exchange, which can cut liquidity, reduce visibility, and often lead to sharper declines in share value—think of it like a venue’s minimum dress code that, if not met, can bar a performer from the stage.

mandatory panel monitor regulatory

"Nasdaq further notified the Company that it will be subject to a Mandatory Panel Monitor"

A mandatory panel monitor is an independent group tasked with regularly reviewing safety and key results during a clinical trial or regulated program to protect participants and ensure the study is conducted properly. For investors, this matters because the panel can recommend changes, pauses, or early stopping of a trial — actions that can speed up, delay, or quietly derail a program and therefore materially affect a company’s timeline and value, much like a referee whose calls change the outcome of a game.

nasdaq hearings panel regulatory

"the Company will have the opportunity to request a hearing with the Nasdaq Hearings Panel."

A Nasdaq hearings panel is a group of experts that reviews cases when a company's stock listing is at risk of being removed from the exchange. They evaluate whether the company has met certain standards and determine if it can keep trading on Nasdaq. This process matters to investors because it can affect a company's ability to raise money and maintain credibility in the market.

AI-generated analysis. Not financial advice.

04/02/2026 - 09:00 AM

CAMBRIDGE, Mass. and HOUSTON, April 2, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (Nasdaq: DCOY) (Decoy, or the Company), announces that on March 31, 2026 the Company received notification from the Nasdaq Stock Market LLC that it has regained compliance with Listing Rule 5550(a)(2), the Minimum Bid Price Requirement and is now in compliance with all other applicable continued listing requirements of The Nasdaq Capital Market.

Nasdaq further notified the Company that it will be subject to a Mandatory Panel Monitor for a period of one year from March 31, 2026. If, within that one-year monitoring period, the Listing Qualifications Staff finds the Company out of compliance with the Minimum Bid Price Requirement that was the subject of the exception, the Staff will issue a delisting determination letter and the Company will have the opportunity to request a hearing with the Nasdaq Hearings Panel.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 regarding Decoy, including expected achievement of milestones for its lead asset and future prospects of Decoy. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the management of Decoy, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "can," "should," "would," "expect," "anticipate," "plan," "likely," "believe," "estimate," "project," "intend," and other similar expressions. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the risk that the Company will not obtain sufficient financing to execute on their business plans and risks related to Decoy's products and development plans, including unanticipated issues with any IND application process and the potential of the IMP³ACT™ platform. Readers are urged to carefully review and consider the various disclosures made by the Company in its reports filed with the SEC, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, as revised or supplemented by its Quarterly Reports on Form 10-Q and other documents filed with the SEC. If one or more of these risks or uncertainties materialize, or if the underlying assumptions prove incorrect, Decoy's actual results may vary materially from those expected or projected.

View original content to download multimedia:https://www.prnewswire.com/news-releases/decoy-therapeutics-regains-compliance-with-nasdaq-minimum-bid-price-requirement-302732823.html

SOURCE Decoy Therapeutics, Inc

FAQ

When did Decoy Therapeutics (DCOY) regain Nasdaq minimum bid price compliance?

Decoy Therapeutics regained compliance with Nasdaq Listing Rule 5550(a)(2) on March 31, 2026. According to the company, this restores its minimum bid price standing and confirms it meets other continued listing requirements at that date.

What does the Mandatory Panel Monitor mean for DCOY shareholders?

The Mandatory Panel Monitor subjects DCOY to additional oversight for one year from March 31, 2026. According to the company, Nasdaq will monitor the listing qualifications staff findings and may act if the company falls out of compliance.

Could Decoy Therapeutics be delisted after regaining compliance?

Yes, Nasdaq may issue a delisting determination if DCOY is found noncompliant during the monitor period. According to the company, a delisting determination would allow the company to request a hearing with the Nasdaq Hearings Panel.

Is Decoy Therapeutics compliant with other Nasdaq listing requirements besides minimum bid price?

Yes, the company is reported to be in compliance with all other applicable continued listing requirements. According to the company, the compliance status covers requirements beyond the minimum bid price rule.

How long will Nasdaq monitor Decoy Therapeutics after regaining compliance (DCOY)?

Nasdaq will monitor Decoy Therapeutics under a Mandatory Panel Monitor for one year from March 31, 2026. According to the company, this monitoring period is tied to the exception that was the subject of review.

Decoy Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement